文献速递乳腺癌

WSG TP-II 试验生存分析:HR+/HER2+早期乳腺癌新辅助双靶联合内分泌对比化疗

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
PubMed 文献 · J Clin Oncol · 2026-05-18

WSG TP-II 是一项多中心随机开放的II期试验,207例HR+/HER2+早期乳腺癌患者1:1随机接受12周新辅助曲妥珠单抗+帕妥珠单抗联合内分泌治疗或每周紫杉醇化疗,主要终点pCR率化疗组优于内分泌组(56.4% vs 23.7%)。5年随访显示内分泌组总生存率100%(95%CI 100.0-100.0),化疗组97.9%(95%CI 95.0-100.0),两组无事件生存和无浸润性疾病生存均良好,支持降阶梯新辅助治疗联合pCR指导的辅助治疗。

要点

  • HR+/HER2+早期乳腺癌新辅助双靶联合内分泌治疗5年总生存率100%。
  • 化疗组pCR率56.4%优于内分泌组23.7%,但5年生存结局两组均优良。
  • 降阶梯新辅助治疗联合pCR指导辅助治疗安全有效。

核心结论

  • HR+/HER2+早期乳腺癌接受降阶梯化疗或内分泌治疗联合曲妥珠单抗+帕妥珠单抗新辅助治疗均获得优异生存结局。
  • WSG TP-II证实pCR指导的降阶梯新辅助治疗策略安全有效且耐受性良好。

研究设计与样本

  • 多中心、随机、开放标签II期试验(WSG TP-II,NCT03272477),207例患者1:1随机分配至两组。
  • 新辅助治疗12周:内分泌治疗+曲妥珠单抗+帕妥珠单抗对比每周紫杉醇+曲妥珠单抗+帕妥珠单抗。
  • 所有患者辅助阶段接受双HER2阻断;非pCR患者必须接受进一步标准化疗,pCR患者化疗可选。

主要发现

  • 5年随访内分泌组总生存率100%(95%CI 100.0-100.0),化疗组97.9%(95%CI 95.0-100.0)。
  • 5年无事件生存-DCIS率内分泌组92.1%(95%CI 86.6-97.9),化疗组94.8%(95%CI 90.5-99.3)。
  • 5年无浸润性疾病生存率内分泌组97.7%(95%CI 94.5-100.0),化疗组79.8%(95%CI 55.6-100.0)。
  • 主要终点分析显示化疗组pCR率56.4%优于内分泌组23.7%。

临床怎么用

  • HR+/HER2+早期乳腺癌可考虑降阶梯新辅助治疗联合双HER2阻断,根据pCR指导辅助治疗决策。
  • 内分泌治疗联合双靶可作为不耐受化疗患者的可选新辅助方案。

局限性

  • II期开放标签试验,样本量207例,生存分析置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The WSG TP-II trial (ClinicalTrials.gov identifier: NCT03272477) was designed to compare the impact of 12 weeks of neoadjuvant trastuzumab + pertuzumab combined with endocrine therapy (ET) versus chemotherapy (once per week paclitaxel) on the pathologic complete response (pCR) rate and survival in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC). Analysis of the primary end point revealed that the pCR rate in the paclitaxel + trastuzumab + pertuzumab arm was superior compared with that in the ET + trastuzumab + pertuzumab arm (56.4% v 23.7%). METHODS: Here, we present the final 5-year survival analysis of this multicenter, randomized phase II, open-label trial, with 207 participants randomly assigned 1:1 to the two study arms. All patients received dual HER2 blockade in the adjuvant setting. Further standard chemotherapy was obligatory in all patients with non-pCR, but optional after pCR. RESULTS: After a 5-year follow-up, an overall survival rate of 100% (95% CI, 100.0 to 100.0) in the ET arm versus 97.9% (95% CI, 95.0 to 100.0) in the paclitaxel arm was estimated. The corresponding 5-year event-free survival-ductal carcinoma in situ rates were 92.1% (95% CI, 86.6 to 97.9) versus 94.8% (95% CI, 90.5 to 99.3), and 5-year invasive disease-free survival rates were 97.7% (95% CI, 94.5 to 100.0) versus 79.8% (95% CI, 55.6 to 100.0). CONCLUSION: Our results show excellent survival outcomes in patients with hormone receptor-positive/HER2-positive eBC who received either a de-escalated chemotherapy or ET in combination with trastuzumab and pertuzumab in the neoadjuvant setting. WSG TP-II confirms the safety and efficacy of a de-escalated and well-tolerated neoadjuvant therapy approach with pCR-guided adjuvant therapy in hormone receptor-positive/HER2-positive eBC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gluz O, Nitz UA, Christgen M, et al. Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. J Clin Oncol. 2026. PMID: 42150145. doi:10.1200/JCO-25-01047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。